These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 35939768)
1. Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. Bedard PL; Li S; Wisinski KB; Yang ES; Limaye SA; Mitchell EP; Zwiebel JA; Moscow JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT JCO Precis Oncol; 2022 Jul; 6():e2200165. PubMed ID: 35939768 [TBL] [Abstract][Full Text] [Related]
2. Phase II Trial of Afatinib in Patients With Gettinger SN; Song Z; Reckamp KL; Moscow JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Kong XT; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT JCO Precis Oncol; 2024 Jul; 8():e2300725. PubMed ID: 38986051 [TBL] [Abstract][Full Text] [Related]
3. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E. Chen MF; Song Z; Yu HA; Sequist LV; Lovly CM; Mitchell EP; Moscow JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Umemura Y; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT JCO Precis Oncol; 2024 Apr; 8():e2300454. PubMed ID: 38591867 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. De Grève J; Moran T; Graas MP; Galdermans D; Vuylsteke P; Canon JL; Schallier D; Decoster L; Teugels E; Massey D; Chand VK; Vansteenkiste J Lung Cancer; 2015 Apr; 88(1):63-9. PubMed ID: 25682316 [TBL] [Abstract][Full Text] [Related]
5. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Jhaveri KL; Wang XV; Makker V; Luoh SW; Mitchell EP; Zwiebel JA; Sharon E; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT Ann Oncol; 2019 Nov; 30(11):1821-1830. PubMed ID: 31504139 [TBL] [Abstract][Full Text] [Related]
6. Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. Kalinsky K; Hong F; McCourt CK; Sachdev JC; Mitchell EP; Zwiebel JA; Doyle LA; McShane LM; Li S; Gray RJ; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Conley BA; O'Dwyer PJ; Harris LN; Arteaga CL; Chen AP; Flaherty KT JAMA Oncol; 2021 Feb; 7(2):271-278. PubMed ID: 33377972 [TBL] [Abstract][Full Text] [Related]
7. Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial. Hickish T; Mehta A; Liu MC; Huang CS; Arora RS; Chang YC; Yang Y; Vladimirov V; Jain M; Tsang J; Pemberton K; Sadrolhefazi B; Jin X; Tseng LM Breast Cancer Res Treat; 2022 Apr; 192(3):593-602. PubMed ID: 35138529 [TBL] [Abstract][Full Text] [Related]
8. Phase II Study of Taselisib in Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919 [TBL] [Abstract][Full Text] [Related]
9. Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J. Connolly RM; Wang V; Hyman DM; Grivas P; Mitchell EP; Wright JJ; Sharon E; Gray RJ; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Wang J; Wisinski KB; Tricoli JV; Conley BA; Harris LN; Arteaga CL; O'Dwyer PJ; Chen AP; Flaherty KT Clin Cancer Res; 2024 Apr; 30(7):1273-1280. PubMed ID: 38433347 [TBL] [Abstract][Full Text] [Related]
10. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Schuler M; Awada A; Harter P; Canon JL; Possinger K; Schmidt M; De Grève J; Neven P; Dirix L; Jonat W; Beckmann MW; Schütte J; Fasching PA; Gottschalk N; Besse-Hammer T; Fleischer F; Wind S; Uttenreuther-Fischer M; Piccart M; Harbeck N Breast Cancer Res Treat; 2012 Aug; 134(3):1149-59. PubMed ID: 22763464 [TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Copanlisib in Patients With Tumors With Damodaran S; Zhao F; Deming DA; Mitchell EP; Wright JJ; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Suga JM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT J Clin Oncol; 2022 May; 40(14):1552-1561. PubMed ID: 35133871 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Lin NU; Winer EP; Wheatley D; Carey LA; Houston S; Mendelson D; Munster P; Frakes L; Kelly S; Garcia AA; Cleator S; Uttenreuther-Fischer M; Jones H; Wind S; Vinisko R; Hickish T Breast Cancer Res Treat; 2012 Jun; 133(3):1057-65. PubMed ID: 22418700 [TBL] [Abstract][Full Text] [Related]
14. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672 [TBL] [Abstract][Full Text] [Related]
15. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer. Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159 [TBL] [Abstract][Full Text] [Related]
16. Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. Kwak EL; Shapiro GI; Cohen SM; Becerra CR; Lenz HJ; Cheng WF; Su WC; Robohn M; Le Maulf F; Lobmeyer MT; Chand VK; Iafrate AJ Cancer; 2013 Aug; 119(16):3043-51. PubMed ID: 23775486 [TBL] [Abstract][Full Text] [Related]
17. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963 [TBL] [Abstract][Full Text] [Related]
18. Phase II Study of Erdafitinib in Patients With Tumors With Gong J; Mita AC; Wei Z; Cheng HH; Mitchell EP; Wright JJ; Ivy SP; Wang V; Gray RC; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Alva AS; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT JCO Precis Oncol; 2024 Apr; 8():e2300406. PubMed ID: 38603651 [TBL] [Abstract][Full Text] [Related]